Feb. 12 at 7:55 AM
$PFE Bullish options activity is heating up after that Q4 double beat. 📈 While the market digests the Metsera tolerability data, the oncology moat from Seagen is already delivering 14% growth. Dividend yield remains a fortress at nearly 6% while we wait for the 2028 growth pivot. The "TrumpRx" initiative is a smart geostrategy play to front-run pricing regs. Watching the
$30 resistance level closely. 🐂💎
#Pfizer #StockMarket #Pharma #Growth
Risk Warning: CFDs are high-risk. 77.95% of retail accounts lose money.